European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

RegulatoryapprovedasedebartPositive

AI Analysis

Summary

Lundbeck's investigational anti-ACTH monoclonal antibody asedebart has received orphan designation from the European Commission for the treatment of Cushing's syndrome of endogenous origin, a rare endocrine disorder.

Outcome Details

European Commission granted orphan designation

Importance:6/10

Sentiment:

0.70

orphan designationmonoclonal antibodyendocrine disorderrare diseaseEuropean Commission

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on August 24, 2026 9:35 AM

Read Original